The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 149K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Owen-Schaub, L. B.
Right arrow Articles by Price, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Owen-Schaub, L. B.
Right arrow Articles by Price, J. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/11/1717/ $5.00
The Journal of Experimental Medicine, Volume 188, Number 9, November 2, 1998 1717-1723


Articles

Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis

Laurie B. Owen-Schaub*, Kenneth L. van Golen{ddagger}, Laurie L. Hill*, and Janet E. Price{ddagger}

From the * Department of Immunology and the {ddagger} Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030

Apoptosis induced by Fas (CD95) ligation is frequently lost during tumor progression; however, there is no direct evidence to support an association of Fas loss-of-function with metastatic tumor behavior. To determine whether Fas loss-of-function is critical for acquisition of the metastatic phenotype, we have compared the ability of Fas-sensitive K1735 murine melanomas to form spontaneous lung metastases in wild-type and Fas ligand–deficient mice. Fas-sensitive melanoma clones are highly tumorigenic but rarely metastatic in wild-type syngeneic mice. However, in Fas ligand–deficient mice, both the incidence and number of metastases are increased. These findings provide the first evidence that Fas–Fas ligand interactions can suppress metastasis and that tumor Fas loss-of-function may be causally linked to metastatic progression.

Key Words: Fas ligand • metastasis • melanoma • apoptosis • lung microenvironment


Address correspondence to Laurie Owen-Schaub, The Department of Immunology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, Houston, TX 77030. Phone: 713-792-2121; Fax: 713-745-1633; E-mail: lowensch{at}mdanderson.org

We would like to acknowledge and thank C.F. Ware (La Jolla Institute for Allergy and Immunology, La Jolla, CA) for providing Fas-Fc and LTβR-Fc; C.D. Bucana for providing expert advice with immunohistochemistry; G. Kiriakova and E. Kruzel for technical assistance; Karen Rameriz for providing technical expertise with flow cytometric analyses; and K. Dunner for assistance with photography.

K.L. van Golen's present address is Department of Internal Medicine, The University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109.

Abbreviations used: FasL, Fas ligand; LCM, lung-conditioned medium.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS